Four randomized phase III trials prospectively compared the efficacy of first generation EGFR-TKIs against standard platinum-based chemotherapy in patients with EGFR mutation-positive NSCLC (61–67). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.